S

Sun Research Institute | San Antonio, TX

Research site
(Unclaimed)
Location
303 E. Quincy Street, Suite 101, San Antonio, Texas, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib
Linaclotide
Bococizumab
Sodium Oxybate
Ritonavir
ABT-494
Semaglutide
Methotrexate
Ozanimod
Xyrem®

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

35 of 120 total trials

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Enrolling
NASH - Nonalcoholic Steatohepatitis
Drug: Placebo
Drug: IVA337

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

Enrolling
Crohn Disease
Drug: Ozanimod
Other: Placebo

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to seve...

Enrolling
Lupus Erythematosus, Systemic
Drug: Cenerimod
Drug: Placebo

We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this b...

Active, not recruiting
Chronic Kidney Disease
Diabetes Mellitus, Type 2
Drug: Placebo (Semaglutide)
Drug: Semaglutide

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 dia...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Placebo (semaglutide)
Drug: Semaglutide

The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and v...

Active, not recruiting
Rheumatoid Arthritis
Drug: Upadacitinib
Drug: Placebo for Adalimumab

A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily fo...

Enrolling
Systemic Lupus Erythematosus
Drug: GLPG3667
Drug: Placebo

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythema...

Enrolling
Systemic Lupus Erythematosus
Drug: Afimetoran
Other: Placebo

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling
Atrial Fibrillation
Drug: Placebo
Drug: Apixaban Placebo

The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal in...

Active, not recruiting
Respiratory Syncytial Virus
Biological: mRNA-1273.214
Biological: mRNA-1345

The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine...

Active, not recruiting
Genital Herpes
Biological: mRNA-1608
Biological: BEXSERO

This is an open-label extension to Study LPCN 1144-18-002. The study is aimed at evaluating the safety and tolerability of LPCN 1144 in adult men wit...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Drug: LPCN 1144

This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric subjects (2 years to \<18 years of age) with IDA, or felt...

Enrolling
Iron Deficiency Anemia
Drug: Iron sucrose
Drug: ferumoxytol

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). T...

Enrolling
Lupus Erythematosus, Systemic
Drug: Litifilimab
Drug: Placebo

The purpose of this study is to evaluate the pre-treatment and single-dose post treatment susceptibility of baloxavir marboxil in participants aged 1...

Enrolling
Influenza
Drug: Baloxavir Marboxil

This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.

Enrolling
Crohn Disease
Drug: Ozanimod

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Obicetrapib
Drug: Placebo

This study will establish a normative database of Tilmanocept Uptake Values (TUVjoint) in healthy controls age-matched to the RA population.

Active, not recruiting
Rheumatoid Arthritis
Drug: Tc99m tilmanocept

The objective of the study is to compare the safety and gastrointestinal tolerability of ferric maltol oral suspension and ferrous sulfate oral liqui...

Enrolling
Anemia
Iron-deficiency
Drug: Ferric Maltol
Drug: Ferrous sulfate

Trial sponsors

Pfizer logo
AbbVie logo
Novo Nordisk logo
Celgene logo
Jazz Pharmaceuticals logo
Lilly logo
M
AstraZeneca logo
Forest Laboratories logo
J

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems